Cargando…
Efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement
BACKGROUND: ROS1 rearrangement is a novel molecular subgroup of non-small-cell lung cancer (NSCLC). This study aimed to investigate the efficacy of crizotinib and pemetrexed-based chemotherapy in Chinese NSCLC patients with ROS1 rearrangement. RESULTS: A total of 2309 patients received ROS1 fusion d...
Autores principales: | Zhang, Limin, Jiang, Tao, Zhao, Chao, Li, Wei, Li, Xuefei, Zhao, Sha, Liu, Xiaozhen, Jia, Yijun, Yang, Hui, Ren, Shengxiang, Zhou, Caicun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5342729/ https://www.ncbi.nlm.nih.gov/pubmed/27738334 http://dx.doi.org/10.18632/oncotarget.12612 |
Ejemplares similares
-
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
por: Wang, Yan, et al.
Publicado: (2018) -
First‐line crizotinib versus platinum‐pemetrexed chemotherapy in patients with advanced ROS1‐rearranged non‐small‐cell lung cancer
por: Shen, Lan, et al.
Publicado: (2020) -
High feasibility of cytological specimens for detection of ROS1 fusion by reverse transcriptase PCR in Chinese patients with advanced non-small-cell lung cancer
por: Zhang, Limin, et al.
Publicado: (2019) -
Crizotinib efficacy in advanced non-squamous NSCLC patients with ALK or ROS1 rearrangement
por: Krawczyk, Paweł, et al.
Publicado: (2021) -
Exosomes transmit T790M mutation‐induced resistance in EGFR‐mutant NSCLC by activating PI3K/AKT signalling pathway
por: Liu, Xiaozhen, et al.
Publicado: (2020)